The Governing Council of the University of Toronto

Study shows combining VIGex gene expression signature and ctDNA analysis improves immunotherapy response prediction in advanced solid tumors, with VIGex-Hot tumors and decreased ctDNA levels indicating greater clinical benefit.

The celebration of treatment X's progression-free survival benefit may be misleading due to informative censoring, where higher toxicity leading to treatment discontinuation skews results in favor of X. Emphasis should shift to overall survival, sensitivity analyses, and time-to-treatment failure to accurately assess clinical benefit.

Cystic fibrosis causes mucus buildup in lungs and digestive system, affecting 40,000 in the U.S. CFTR modulators like Vertex's Trikafta treat symptoms by correcting the CFTR protein. Five biotech companies—Enterprise Therapeutics, Krystal Biotech, Recode Therapeutics, Sionna Therapeutics, and Vertex Pharmaceuticals—are developing transformative treatments, including nebulized formulations, gene therapies, and small molecules targeting CFTR mutations. The global cystic fibrosis therapeutics market is growing, but high drug prices remain a concern.

Paul J. Karanicolas, MD, PhD, FRCSC presents 'Tranexamic Acid in Patients Undergoing Liver Resection: The HeLiX Randomized Clinical Trial' on Nov 22, 2024, 1-2 p.m. ET. Join via Zoom link with passcode 003222.

Combination of cognitive rehabilitation (CR) and transcranial direct current stimulation (tDCS) may slow cognitive decline in high-risk older adults, particularly those with remitted major depressive disorder (rMDD) and low genetic risk for Alzheimer’s disease.

Developed EPPIIC checklist addresses limitations in existing PPI evaluation tools, focusing on Policy & Practice, Participatory Culture, and Influence & Impact, aiming to enhance PPI in clinical trials.

Insilico Medicine secures $100M revolving loan from HSBC to expand its AI-driven drug discovery pipeline and upgrade Pharma.AI platform, aiming to revolutionize healthcare and meet unmet clinical needs.

Healthy adults have been dosed in a Phase 1 trial of Lucid-21-302, a potential myelin-protective oral treatment for multiple sclerosis. The trial aims to assess safety and tolerability, with findings expected to inform a Phase 2 trial on efficacy in MS patients. Lucid-MS is designed to protect and possibly repair myelin sheath damage without affecting the immune system.

Dr. Matthew Ladda, a new family doctor in Collingwood, has quickly filled his roster with 450 patients from local wait-lists. He faces significant work catching up unattached patients, reviewing thousands of pages of old records. Ladda, who grew up in New Brunswick and trained at U of T and U of Western, has seen an influx of patients from other South Georgian Bay communities due to the family medicine crisis. Municipalities are investing in physician recruitment, with Collingwood offering incentives and joining a letter to the province urging action on the doctor shortage.

Dr. Matthew Ladda, a new family doctor in Collingwood, has quickly filled his roster with 450 patients from local wait lists. He faces significant work to catch up patients who have been unattached for years, reviewing thousands of pages of old records. Ladda, who grew up in New Brunswick and trained at the University of Toronto, is committed to providing care in Collingwood for at least five years. Municipalities in South Georgian Bay are investing in physician recruitment to address the ongoing crisis in family medicine, with an estimated 6,000-7,000 people in the region lacking a local family doctor.